Nihar R Pandey,Daniel L Sparks
Nihar R Pandey
A uniquely formulated soy phospholipid is being developed as a potential therapeutic for the treatment and prevention of heart disease. Three phase I and one phase I/II clinical trials have been completed with soy phosphatidylinositol (PI)....
Pharmacological therapies for raising HDL cholesterol beyond synthetic small molecules [0.03%]
合成小分子之外提高HDL胆固醇的药理学疗法
Ricardo A Garcia
Ricardo A Garcia
Epidemiological studies support the hypothesis that HDL particles possess inherent atheroprotective properties. The protective properties of HDL are primarily attributed to its known involvement in cholesterol mobilization from peripheral t...
Robert Kisilevsky,Shui-Pang Tam,John B Ancsin
Robert Kisilevsky
Serum amyloid A (SAA) inhibits acyl coenzyme A cholesterol acyltransferase and enhances cholesterol esterase activities, shifting stored esterified cholesterol to free cholesterol (the exportable form). The SAA domains responsible for these...
Ultrasound carotid artery intima-media thickness assessment for progression of atherosclerosis in lipid intervention studies [0.03%]
超声检测颈动脉内膜中层厚度在血脂干预研究中评价动脉粥样硬化进展中的应用
Tasneem Z Naqvi
Tasneem Z Naqvi
Atherosclerotic cardiovascular disease is the number one cause of death in Western countries and is a rapidly growing problem worldwide. The majority of patients who present with acute coronary syndrome often have a low cardiovascular risk ...
Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis [0.03%]
核受体在肥胖、脂质异常和动脉粥样硬化中的药物靶点作用
Michael K Hansen,Thomas M Connolly
Michael K Hansen
Nuclear hormone receptors, including peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), and the farnesoid X receptor (FXR), are transcription factors involved in the regulation of essential metabolic functions, i...
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections [0.03%]
一种治疗耐药金黄色葡萄球菌感染药物的潜在候选者iclапrim的研究进展
William J Peppard,Christopher D Schuenke
William J Peppard
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and sk...
Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection [0.03%]
新型抗生素注射用头孢他林葡甲胺用于治疗耐甲氧西林金黄色葡萄球菌感染研究
Daniel Parish,Noah Scheinfeld
Daniel Parish
Forest Laboratories (following its acquisition of Cerexa Inc, a spin-out from Peninsula Pharmaceuticals Inc), under license from Takeda, is developing ceftaroline fosamil, an N-phosphono prodrug of ceftaroline, a derivative of a fourth-gene...
PRO-2000, an antimicrobial gel for the potential prevention of HIV infection [0.03%]
PRO-2000抑菌凝胶预防HIV感染潜性候选药物
Patricia S Fletcher,Robin J Shattock
Patricia S Fletcher
Indevus Pharmaceuticals Inc, under license from Paligent Inc, is developing PRO-2000, an antimicrobial gel for the prevention of HIV infection. The company is also investigating its potential to prevent the transmission of other sexually tr...
Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases [0.03%]
宿主和微生物细胞作为治疗感染性疾病的武装抗体靶点
Ekaterina Dadachova,Arturo Casadevall
Ekaterina Dadachova
There is a renewed interest in antibody-based therapy for infectious diseases. Antibodies armed with different cytotoxic agents such as toxins, drugs or radionuclides can specifically target virally infected host cells or microbes themselve...